<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35034333</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2240-2993</ISSN><JournalIssue CitedMedium="Internet"><Volume>122</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta neurologica Belgica</Title><ISOAbbreviation>Acta Neurol Belg</ISOAbbreviation></Journal><ArticleTitle>The frequency of ALSFRS-R reversals and plateaus in patients with limb-onset amyotrophic lateral sclerosis: a cohort study.</ArticleTitle><Pagination><StartPage>1567</StartPage><EndPage>1573</EndPage><MedlinePgn>1567-1573</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13760-021-01849-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder, ALS patients might show reversals or plateaus of ALS Functional rating scale-revised (ALSFRS-R) scores during follow-up, which might cast the doubt on the diagnosis. The study aims to determine the frequency of reversals and plateaus of ALSFRS-R score in patients with limb-onset ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and fifty four patients with limb-onset ALS were prospectively recruited. ALSFRS-R scores were followed up every 3 months for at least 1&#xa0;year. The changes between two follow-up points in ALSFRS-R score were compared.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Totally 95 (61.7%) participants showed 85 times plateau and 69 times reversal in ALSFRS score during the 12-month follow-up when compared the ALSFRS-R score between two adjacent follow-up points. Reversal and plateau in ALSFRS-R score were detected in 31.8% patients between initial and 3 months, 18.8% between 3 and 6 months, 22.7% between 6 and 9 months, 22.7% between 9 and 12 months, respectively. When comparing with the ALSFRS-R score in the baseline, reversal and plateau in ALSFRS-R score were detected in 31.8% patients at 3 months, 14.9% at 6 months, 6.5% at 9 months, 5.8% at 12 months, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Plateaus and reversals in ALSFRS-R score were common in limb-onset ALS patients during follow-up. A relatively stable or reversal in the ALS-FRS-R score does not exclude the diagnosis of ALS. Limitations of ALSFRS-R score as an outcome parameter in clinical trial should be further evaluated.</AbstractText><CopyrightInformation>&#xa9; 2021. Belgian Neurological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Dongchao</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xunzhe</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Liying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingsheng</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0257-5345</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China. liumingsheng_pumch@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2019ZX09734001</GrantID><Agency>National Major Science and Technology Projects of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Acta Neurol Belg</MedlineTA><NlmUniqueID>0247035</NlmUniqueID><ISSNLinking>0300-9009</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R score</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Plateaus</Keyword><Keyword MajorTopicYN="N">Reversals</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>16</Day><Hour>21</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35034333</ArticleId><ArticleId IdType="doi">10.1007/s13760-021-01849-1</ArticleId><ArticleId IdType="pii">10.1007/s13760-021-01849-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cleveland DW, Rothstein JD (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2(11):806&#x2013;819</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35097565</ArticleId><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG (2009) Updates on amyotrophic lateral sclerosis: improving patient care. Ann Neurol 65(Suppl 1):S1-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21546</ArticleId><ArticleId IdType="pubmed">19191303</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293&#x2013;299</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Nodera H, Izumi Y, Kaji R (2007) New diagnostic criteria of ALS (Awaji criteria). Brain Nerve 59(10):1023&#x2013;1029</Citation><ArticleIdList><ArticleId IdType="pubmed">17969342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K et al (2008) ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 275(1&#x2013;2):69&#x2013;73</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.07.016</ArticleId><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS et al (2016) How common are ALS plateaus and reversals? Neurology 86(9):808&#x2013;812</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002251</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId><ArticleId IdType="pmc">4793781</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R et al (2020) Plateaus in amyotrophic lateral sclerosis progression: results from a population-based cohort. Eur J Neurol 27(8):1397&#x2013;1404</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14287</ArticleId><ArticleId IdType="pubmed">32346913</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM et al (1999) The ALSFRS-R a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1&#x2013;2):13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu L et al (2017) Prevalence and risk factors of prehypertension and hypertension in southern China. PLoS ONE 12(1):e0170238</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0170238</ArticleId><ArticleId IdType="pubmed">28095471</ArticleId><ArticleId IdType="pmc">5240940</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou X et al (2013) Impact of waist circumference and body mass index on risk of cardiometabolic disorder and cardiovascular disease in Chinese adults: a national diabetes and metabolic disorders survey. PLoS ONE 8(3):e57319</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057319</ArticleId><ArticleId IdType="pubmed">23520466</ArticleId><ArticleId IdType="pmc">3592870</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J et al (2017) What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 88(5):381&#x2013;385</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-314661</ArticleId><ArticleId IdType="pubmed">27888187</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H (2017) Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin Pharmacother 18(7):735&#x2013;738</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PC et al (2020) Tamoxifen for amyotrophic lateral sclerosis: a randomized double-blind clinical trial. Medicine (Baltimore) 99(22):e20423</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000020423</ArticleId><ArticleId IdType="pubmed">32481440</ArticleId></ArticleIdList></Reference><Reference><Citation>Edaravone (MCI-186) ALS 19 Study Group (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol&#xa0;16(7):505&#x2013;512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS et al (2020) Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 21(1&#x2013;2):5&#x2013;14</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Offen D et al (2009) Spinal cord mRNA profile in patients with ALS: comparison with transgenic mice expressing the human SOD-1 mutant. J Mol Neurosci 38(2):85&#x2013;93</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-007-9004-z</ArticleId><ArticleId IdType="pubmed">18651250</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, Vande-Velde C, Cleveland DW (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52(1):39&#x2013;59</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J, Comley LH, Hedlund E (2017) Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol 133(6):863&#x2013;885</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1708-8</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId><ArticleId IdType="pmc">5427160</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer AM, Sanes JR, Lichtman JW (2005) A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J Comp Neurol 490(3):209&#x2013;219</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.20620</ArticleId><ArticleId IdType="pubmed">16082680</ArticleId></ArticleIdList></Reference><Reference><Citation>Felice KJ (1997) A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 20(2):179&#x2013;185</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4598(199702)20:2&lt;179::AID-MUS7&gt;3.0.CO;2-9</ArticleId><ArticleId IdType="pubmed">9040656</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Bello-Haas V, Florence JM (2013) Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev 2013(5):CD005229</Citation></Reference><Reference><Citation>Reich-Slotky R et al (2013) Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 14(3):212&#x2013;216</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.770028</ArticleId><ArticleId IdType="pubmed">23452274</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y et al (2015) Association between nutritional status and disease severity using the amyotrophic lateral sclerosis (ALS) functional rating scale in ALS patients. Nutrition 31(11&#x2013;12):1362&#x2013;1367</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2015.05.025</ArticleId><ArticleId IdType="pubmed">26429656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F et al (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66(2):265&#x2013;267</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>